Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor type 1 blockers (ARB) are undisputedly the first line drugs in combating renal fibrosis. These drugs, however, are not able to halt the progression completely and in some conditions, like aristocholic acid-induced renal fibrosis in rats, they are
No takes yet. Share an insight, caveat, or question.
Boor et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: